Dr. Betty Chang

Head of Research, Oncology & Inflammation‍

Dr. Betty Chang

Betty Y. Chang, Ph.D., is our Head of Research, Oncology and Inflammation, leading efforts for discovering new molecules for our growing pipeline.

Prior to Summit, Dr. Chang was Senior Vice President of Translational Research and Early Development, part of the executive team, of Molecular Templates, Inc., an immunotoxin company where she was responsible for nonclinical toxicology, clinical pharmacology, bioanalytical and translational medicine functions. From 2018 to 2019, she was Chief Operating Officer and Executive Vice President of Product Development at Angarus Therapeutics, an early-stage start-up of innate immunity activating molecules.

From 2009 to 2018, she was at Pharmacyclics, Inc., (acquired by AbbVie, Inc. in 2015) where she was ultimately the Head and Vice President of Research. In that function, she built and led the strategy and operations of a team responsible for drug discovery, pharmacology, translational medicine, over 100+ academic research collaborations (MTA/SRA) and early development activities for ibrutinib. Dr. Chang started her career at Cell Genesys, Inc., a gene / cell therapy company in 1999, and then was Associate Director at Rigel and Alder Biopharmaceuticals, with increasing responsibilities in research and development.

Dr. Chang has published over 100 research manuscripts, conference abstracts, and patent publications. Dr. Chang received her Ph.D. degree in Biochemistry and Molecular Biology from the University of California, Davis, and completed her postdoctoral fellowship in cancer biology at Stanford School of Medicine.